Patient Care: GLP-1 Mimetic Semaglutide Is Effective Across Ejection Fraction in Patients with HFpEF and Obesity: New STEP-HFpEF Analysis

Results from the prespecified analysis of STEP-HFpEF demonstrated that semaglutide, a glucagon-like peptide-1 (GLP-1) mimetic, improved scores on the Kansas City Cardiomyopathy Questionnaire Clinical Summary (KCCQ-CSS) and also led to reductions in body weight and systemic inflammation across LVEF categories in persons with the obesity phenotype of HFpEF.

The findings, wrote study authors in the Journal of the American College of Cardiology, support, “the potential for use of semaglutide in patients with the obesity phenotype of HFpEF regardless of EF.”

The study was led by renowned cardiologist Mikhail Kosiborod, MD, vice president of research at Saint Luke's Health System, director of cardiometabolic research and co-director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute.

Read the full Patient Care article: GLP-1 Mimetic Semaglutide Is Effective Across Ejection Fraction in Patients with HFpEF and Obesity: New STEP-HFpEF Analysis